PD-1 Inhibitors: Patients received PD-1 inhibitors mono- or combined therapy in real-world clinical practice
Study summary
This retrospective study will leverage previous immune function monitoring results in conjunction with clinical case data at this medical center.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. Age ≥18 years.
2. Pathologically confirmed malignant tumors.
3. Complete medical records.
4. Assessable immune function test data.
Exclusion Criteria:
1. Age \<18 years.
2. No confirmed tumor pathology.
3. Untraceable medical records.
4. Non-assessable immune function tests.
Primary outcome measure(s)
Objective response rate — 6 months The objective response rate at 6 months
Adverse events — 1 year Number of participants who experienced immune-related adverse events at 1 year according to CTCAE 5.0
Trial sites (1)
Facility
City
Region
Status
Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.